Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 3

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Plasma cell 1Breast 1

Conditions

Breast Neoplasms 9481Neoplasms 6589Prostatic Neoplasms 4399Colorectal Neoplasms 3978Lung Neoplasms 3644Carcinoma, Non-Small-Cell Lung 3585Pancreatic Neoplasms 2479Carcinoma, Hepatocellular 2413Leukemia, Myeloid, Acute 2265Multiple Myeloma 2121Stomach Neoplasms 2109Neoplasm Metastasis 1911Head and Neck Neoplasms 1870Ovarian Neoplasms 1773Precursor Cell Lymphoblastic Leukemia-Lymphoma 1734Lymphoma 1730Brain Neoplasms 1702Rectal Neoplasms 1676Melanoma 1656Colonic Neoplasms 1629Leukemia 1500Uterine Cervical Neoplasms 1499Recurrence 1486Esophageal Neoplasms 1312Glioblastoma 1308Lymphoma, Non-Hodgkin 1205Leukemia, Lymphocytic, Chronic, B-Cell 1120Squamous Cell Carcinoma of Head and Neck 1109Urinary Bladder Neoplasms 1078Lymphoma, Follicular 1067

Interventions

Exercise Therapy 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Heart Failure, Systolic × Clear all
NCT02018497 2023-09-21

ESSENTIAL

CES University

Unknown
5,000 enrolled

Atrial Fibrillation, Autonomic Nervous System Diseases, Ischemic Attack, Transient, Cerebrovascular Disorders, Coronary Disease, Depression, Diabetes Mellitus, Fibromyalgia, Hypotension, Neoplasms, Syncope, Fatigue Syndrome, Chronic, Panic Disorder, Syncope, Vasovagal, Acute Coronary Syndrome, Heart Failure, Systolic, Heart Failure, Diastolic

NCT02026505 2019-03-13

Evaluation of Cardiotoxic Effects of Bortezomib

Oregon Health and Science University

Completed
11 enrolled
Plasma cell

Multiple Myeloma, Heart Failure, Systolic

NCT03089502 2018-10-12

CORE

University Health Network, Toronto

Phase NA Terminated
2 enrolled
Breast

Breast Neoplasms, Motor Activity, Ventricular Dysfunction, Left, Heart Failure, Systolic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡